Ellorarxine, a groundbreaking drug compound developed by Nevrargenics, is showing remarkable promise in the treatment of Amyotrophic Lateral Sclerosis (ALS) and has recently received approval from the MHRA to advance to human trials. This news brings a glimmer of hope to the over 5,000 individuals
Clinical Outcome Assessments (COAs) play a pivotal role in the drug development process. These tools, which measure the impact of a treatment on patients' health status, encompass several types: Patient-Reported Outcomes (PROs), Clinician-Reported Outcomes (ClinROs), Observer-Reported Outcomes
Lundbeck, the Danish drugmaker, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion, centering the deal around Longboard's promising experimental brain medicine, bexicaserin. This medicine is in late-stage clinical testing for treating developmental and epileptic
In a significant development for global health preparedness, RedHill Biopharma Ltd. has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to advance opaganib, a promising treatment for Ebola virus disease (EBOV). This collaboration marks a crucial step in combating
The biopharmaceutical industry is persistently advancing, fueled by innovations and strategic alliances designed to tackle some of the toughest medical challenges. A particularly promising collaboration that has emerged is the partnership between Matica Biotechnology Inc. (Matica Bio) and
The approval of Bluebird bio's gene therapy, Skysona, in September 2022 by the FDA marked a significant milestone for treating cerebral adrenoleukodystrophy (CALD), a rare and fatal childhood brain disorder. Skysona's innovation generated hope for families dealing with CALD, yet recent developments
